Clinical trial NCT06992713: A Clinical Study Evaluating H1710 for Injection in Participants With Advanced Solid Tumors
Official title: A Phase Ia, First-in-human, Clinical Study of the Safety, Tolerability, and Pharmacokinetics of H1710 for Injection in Participants With Advanced Solid Tumors
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: PHASE1
Conditions: Advanced Solid Tumor
Lead sponsor: Shenzhen Hepalink Pharmaceutical Group Co., Ltd.
Sponsor class: INDUSTRY
First posted: 2025-05-28
Enrollment: 36
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This is a phase Ia clinical study evaluating H1710 for Injection in Participants with advanced solid tumors.

Detailed description: The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of H1710 for Injection in participants with advanced solid tumors.

Eligibility criteria: Inclusion Criteria:

* Adults 18 years≤ age ≤ 75 years, irrespective of gender, ethnicity, financial, and educational background.
* Signed Informed Consent Form (ICF) prior to screening.
* Participants with histologically or cytologically confirmed advanced solid tumors, who have failed standard treatment, or have no standard treatment, or intolerant to or not suitable for standard treatment.
* Participants must have measurable or evaluable lesion according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.
* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
* Predicted life expectancy of at least 3 months.
* Adequate bone marrow reserve and organ function within 7 days prior to first dose of H1710.

Exclusion Criteria:

* Presence of malignant tumor lesion(s) that is/are at high risk of bleeding as judged by the clinical study investigator.
* Active clinically significant bleeding or conditions with a high risk of hemorrhage.
* Major surgery or interventional therapy or significant trauma within 28 days prior to the first dose of H1710, or elective surgery during the clinical trial period.
* Spinal or epidural anesthesia or loco-regional anesthesia within 24 hours prior to the first dose of H1710.
* Primary brain tumors. Active brain/meningeal metastases or central nervous system involvement who have clinical symptoms requiring medical intervention within 28 days prior to the first dose of H1710.
* Poorly controlled pleural effusion, pericardial effusion or ascites requiring repeated drainage as determined by investigators to be unsuitable for inclusion.
* Any anti-tumor therapy within 28 days prior to first dose of H1710, except for those who can be included after judgment by investigators.
* Participants have another active invasive malignancy, except for those who can be included after judgment by investigators.
* Symptomatic congestive heart failure, unstable angina, sinus bradycardia, clinically uncontrollable hypertension, and ongoing cardiac arrhythmia.
* Uncontrolled diabetes as determined by investigators.
* History of clinically significant interstitial lung disease or pneumonia as determined by investigators.
* Participants have a history of myocardial infarction within 6 months or coronary stenting within 12 months or a history of arterial thromboembolic event within 3 months before the first dose of H1710.
* Participants received a live attenuated vaccine within 28 days before the first dose of H1710 and/or plan to receive live vaccines during the study period unless approved by the clinical investigator and Sponsor.
* Human immunodeficiency virus (HIV) infection or HIV positive, active Hepatitis B Virus (HBV) infection, active Hepatitis C Virus (HCV) infection. Except those who can be included after judgment by investigators.
* Participants who have active bacterial, fungal or viral (except hepatitis virus) infections within 14 days before the first dose of H1710 and require intravenous or oral administration of antibiotics and/or other anti-infective therapeutic drugs.
* Any adverse events due to prior anti-tumor therapy unresolved to ≤ Grade 1 of CTCAE 5.0 (except for toxicities judged by the clinical investigator to be of no safety risk, such as alopecia, other long term ≤ Grade 2 toxicities which would not impact the administration of H1710 and safety evaluation).
* Participation in a clinical study of biological drug within 28 days, or within 14 days or 5 half-lives for small-molecule agents, before first dose of H1710, or current participation in other therapeutic investigational clinical trials.
* Females who are pregnant or lactating or who intend to become pregnant during the clinical trial period and within 6 months after discontinuation of H1710 treatment. Female or Male who refuse using reliable birth control methods during the clinical trial period and within 6 months after discontinuation of H1710.
* Participants who have any clinically significant psychiatric, social, or medical condition that, as judged by the clinical investigator, could increase the subject's risk, interfere with protocol adherence, or affect the subject's ability to give informed consent are ineligible to participate in the study.

Primary outcomes:
measure: Incidence and severity of treatment-emergent adverse events
timeFrame: Up to ~ 18 months
measure: Dose Limiting Toxicities（DLT）
timeFrame: Up to ~ 18 months
measure: Maximum Tolerated Dose (MTD)
timeFrame: Up to ~ 18 months
measure: Recommended Phase 2 Dose (RP2D)
timeFrame: Up to ~ 18 months
Secondary outcomes:
measure: Maximum Observed Concentration(Cmax) of H1710
timeFrame: Up to ~ 18 months
measure: Time of Maximum Concentration (Tmax)of H1710
timeFrame: Up to ~ 18 months
measure: Area Under the Concentration (AUC) of H1710
timeFrame: Up to ~ 18 months
measure: Terminal Half life( t½) of H1710
timeFrame: Up to ~ 18 months
measure: Clearance (CL) of H1710
timeFrame: Up to ~ 18 months
measure: Objective Response Rate (ORR)
timeFrame: Up to ~ 18 months
measure: Disease Control Rate(DCR)
timeFrame: Up to ~ 18 months
measure: Duration of Response (DOR)
timeFrame: Up to ~ 18 months]
measure: Progression Free Survival (PFS)
timeFrame: Up to ~ 18 months
Other outcomes:
Locations:
Study officials:
References: